BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Phase 2

Completed

Conditions: Diabetic Kidney Disease

Interventions: Drug: Fulacimstat (BAY1142524)
Drug: Placebo

First Posted Date: 2018-01-26

Last Posted Date: 2022-03-03

Lead Sponsor: Bayer

Target Recruit Count: 152

Registration Number: NCT03412006

Locations: 🇧🇬
Med. Center Equita, Varna, Bulgaria
🇫🇮
TAYS TKI Keskus Tutkimusvastaanotto, Tampere, Finland
🇮🇱
The Nazareth Trust Hospital EMMS, Nazareth, Israel

and more 24 locations

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Phase 1

Completed

Conditions: Uterine Fibroids
Endometriosis

Interventions: Drug: Vilaprisan (BAY1002670)

First Posted Date: 2018-01-26

Last Posted Date: 2019-12-03

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT03411980

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Transitional Cell

Interventions: Drug: Rogaratinib (BAY1163877)
Drug: Chemotherapy

First Posted Date: 2018-01-25

Last Posted Date: 2022-09-28

Lead Sponsor: Bayer

Target Recruit Count: 175

Registration Number: NCT03410693

Locations: 🇺🇸
Summit Cancer Center, Spokane, Washington, United States
🇨🇦
Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada
🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

and more 158 locations

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

Completed

Conditions: Pulmonary Embolism

Interventions: Drug: Rivaroxaban(Xarelto, BAY 59-7939)

First Posted Date: 2018-01-25

Last Posted Date: 2022-12-27

Lead Sponsor: Bayer

Target Recruit Count: 288

Registration Number: NCT03410706

Locations: 🇨🇳
Many locations, Multiple Locations, China

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2018-01-23

Last Posted Date: 2018-06-21

Lead Sponsor: Bayer

Target Recruit Count: 120

Registration Number: NCT03408093

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

Completed

Conditions: Hemophilia A

Interventions: Drug: FVIII products
Drug: Conventional FVIII replacement therapies

First Posted Date: 2018-01-23

Last Posted Date: 2018-09-27

Lead Sponsor: Bayer

Target Recruit Count: 160

Registration Number: NCT03405337

Locations: 🇺🇸
Many Locations, Whippany, New Jersey, United States

A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Naproxen Sodium (Aleve, BAY117031)
Drug: Ibuprofen (Advil)
Drug: Placebo

First Posted Date: 2018-01-19

Last Posted Date: 2019-07-18

Lead Sponsor: Bayer

Target Recruit Count: 387

Registration Number: NCT03404206

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: BAY2402234

First Posted Date: 2018-01-19

Last Posted Date: 2022-01-11

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT03404726

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇫🇷
Institut Gustave Roussy, Villejuif Cedex, France

and more 2 locations

Renal Impairment Study

Phase 1

Completed

Conditions: Clinical Trial, Phase I

Interventions: Drug: Fulacimstat (BAY1142524)

First Posted Date: 2018-01-18

Last Posted Date: 2020-03-16

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT03402438

Locations: 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Phase 3

Terminated

Conditions: Uterine Fibroids

Interventions: Drug: Vilaprisan (BAY1002670)
Drug: Placebo

First Posted Date: 2018-01-17

Last Posted Date: 2022-06-30

Lead Sponsor: Bayer

Target Recruit Count: 103

Registration Number: NCT03400956

Locations: 🇺🇦
Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine
🇯🇵
Matsudo City General Hospital, Matsudo, Chiba, Japan
🇯🇵
Tokeidai Memorial Clinic, Sapporo, Hokkaido, Japan

and more 82 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy